(5E)-5-{[(3,4-dichlorophenyl)carbamoyl]imino}-3-(2-phenylethyl)-4,5-dihydro-1,2,3-oxadiazol-3-ium-4-ide | 67629-52-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (5E)-5-{[(3,4-dichlorophenyl)carbamoyl]imino}-3-(2-phenylethyl)-4,5-dihydro-1,2,3-oxadiazol-3-ium-4-ide
• 英文别名: N-(3,4-dichlorophenyl)-N'-[3-(2-phenylethyl)oxadiazol-3-ium-5-yl]carbamimidate
• CAS: 67629-52-1
• 化学式: C17H14Cl2N4O2
• 分子量: 377.2
• InChiKey: DEVIBLJUXPTNNN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  77.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• SYDNONIMINES - SPECIFIC DOPAMINE REUPTAKE INHIBITORS AND THEIR USE IN TREATING DOPAMINE RELATED DISORDERS
  申请人：Chen Hao

  公开号：US20080319030A1

  公开（公告）日：2008-12-25

  Derivatives of Sydnonimine and its analogues, which bind selectively to dopamine transporter (DAT) proteins are useful for treating and delaying the progression of disorders and illnesses that are alleviated by inhibiting dopamine reuptake.

  Sydnonimine及其类似物的衍生物，可以选择性地结合多巴胺转运蛋白（DAT），对于治疗和延缓通过抑制多巴胺再摄取而缓解的疾病和疾病的进展是有用的。
• SYDNONIMINES-SPECIFIC DOPAMINE REUPTAKE INHIBITORS AND THEIR USE IN TREATING DOPAMINE RELATED DISORDERS
  申请人：Chen Hao

  公开号：US20090215839A1

  公开（公告）日：2009-08-27

  Derivatives of Sydnonimine and its analogues, which bind selectively to dopamine transporter (DAT) proteins are useful for treating and delaying the progression of disorders and illnesses that are alleviated by inhibiting dopamine reuptake.

  Sydnonimine及其类似物的衍生物，能够选择性地与多巴胺转运体（DAT）蛋白结合，对于治疗和延缓通过抑制多巴胺再摄取缓解的疾病和疾病的进展非常有用。
• SYDNONIMINES-SPECIFIC DOPAMINE REUPTAKE INHIBITORS AD THEIR USE IN TREATING DOPAMINE RELATED DISORDERS
  申请人：Chen Hao

  公开号：US20110288137A1

  公开（公告）日：2011-11-24

  Derivatives of Sydnonimine and its analogues, which bind selectively to dopamine transporter (DAT) proteins are useful for treating and delaying the progression of disorders and illnesses that are alleviated by inhibiting dopamine reuptake.

  Sydnonimine及其类似物的衍生物，可以选择性地与多巴胺转运蛋白（DAT）结合，对于治疗和延缓通过抑制多巴胺再摄取缓解的疾病和疾病的进展是有用的。
• Methods of treating sleep disorders
  申请人：Melior Pharmaceuticals II, LLC

  公开号：US10188651B2

  公开（公告）日：2019-01-29

  The present disclosure describes compounds and pharmaceutically acceptable salts thereof and compositions and formulations comprising the same that are useful in methods of treating dyskinesia or related disorders, and methods for treating dyskinesia or related disorders.

  本公开描述了可用于治疗运动障碍或相关疾病的化合物及其药学上可接受的盐，以及包含这些化合物的组合物和制剂，以及治疗运动障碍或相关疾病的方法。
• Methods of treating dyskinesia and related disorders
  申请人：Melior Pharmaceuticals II, LLC

  公开号：US11351169B2

  公开（公告）日：2022-06-07

  The present disclosure describes compounds and pharmaceutically acceptable salts thereof and compositions and formulations comprising the same that are useful in methods of treating dyskinesia or related disorders, and methods for treating dyskinesia or related disorders.

  本公开描述了可用于治疗运动障碍或相关疾病的化合物及其药学上可接受的盐，以及包含这些化合物的组合物和制剂，以及治疗运动障碍或相关疾病的方法。